One of the most promising directions in tumor immunotherapy involves the combination of starvation/oxidation therapy with the blockade of negative regulatory pathways, such as the immune checkpoint protein indoleamine 2,3-dioxygenase (IDO). The gene discussed is IDO1; the disease is neoplasm.